Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Summary of Conference Call Records Industry Overview - The pharmaceutical sector is experiencing structural heat, with certain stocks entering a value range, indicating potential for rebound. The focus for 2026 includes three main narratives: innovation going global, turnaround from difficulties, and impulse-driven growth, particularly in BD 2.0, small nucleic acids, and supply chains [1][2] Key Insights and Arguments - The CRO (Contract Research Organization) industry has seen short-term risks largely mitigated, with limited impact from the U.S. NBA 2026 Act. The CRO supply chain is expected to experience a resonance of internal and external demand starting in 2024, leading to a strong fundamental outlook by 2026 [1][4] - In the clinical CRO space, companies like Tigermed are showing significant order growth, with EPS expected to experience nonlinear growth, enhancing stock price elasticity. The peptide CDMO (Contract Development and Manufacturing Organization) sector is also expected to grow at least 25% by 2026, with companies like WuXi AppTec and Notch being noteworthy [1][4][5] - CDMO companies are driven by large product orders, with ADC (Antibody-Drug Conjugates) and small nucleic acids identified as key future growth areas. ADC commercialization is entering a boom phase, benefiting companies like WuXi Biologics, Haoyuan, and Kelaiying [1][6] Additional Important Content - The Ant Group's healthcare model, Antifufu, aims to become a leading health service consultation platform, targeting 500 million registered users and over 100 million monthly active users by the end of 2026. The healthcare team has been elevated to a business group, aiming for revenue exceeding 100 billion [2][7] - Antifufu's technology is based on the "Bailing" general model, integrating Deepseek and Tongyi Qianwen technologies, utilizing proprietary medical data from various sources, including 700 million medical insurance users and 40,000 doctors from acquired platforms [2][8] - User retention strategies for Antifufu include health goal setting and integration with wearable devices, aiming for increased interaction frequency [2][9] - The commercialization strategy includes paid consultations, medication purchases, and health membership services, with B2B collaborations with insurance companies for disease-specific insurance products [2][10] - Collaboration with Alibaba Health leverages a vast user base and medical data, enhancing competitive advantages in the healthcare sector [2][11] - The AI-powered "Famous Doctor Avatar" service is currently in a testing phase, with plans for monetization contingent on achieving high diagnostic accuracy [2][12]

《生物安全法案》复盘 --如何看待地缘政治对中国CXO企业的影响？ 行业研究 · 行业专题 医药生物 · 医疗研发外包 投资评级：优于大市（维持评级） 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 请务必阅读正文之后的免责声明及其项下所有内容 1 报告摘要 证券研究报告 | 2025年12月28日 n 靴子落地，美国《2026财年国防授权法案》夹带《生物安全法案》生效。 请务必阅读正文之后的免责声明及其项下所有内容 2 ü 《2026财年国防授权法案》夹带《生物安全法案》（主要指第851节《禁止与特定生物技术公司签订合同》）落地，标志着美国已将生物安全正式纳入国家防务与 安全战略框架统筹考量，同时彰显其在生物技术供应链自主可控的明确政策转向，本质是中美的科技竞争与产业安全博弈在生物领域的延 ...

证券研究报告 | 2025年12月26日 | 晨会纪要 | | --- | 行业与公司 | 数据日期:2025-12-25 | 上证综指 | 深证成指沪深 | 300 指数 | 中小板综指 | 创业板综指 | 科创 50 | | --- | --- | --- | --- | --- | --- | --- | | 收盘指数（点） | 3959.62 | 13531.41 | 4642.53 | 14517.25 | 3938.41 | 1349.05 | | 涨跌幅度（%） | 0.47 | 0.33 | 0.18 | 0.70 | 0.69 | -0.22 | | 成交金额（亿元） | 7850.18 | 11395.04 | 3853.56 | 4151.46 | 5262.93 | 448.28 | 【常规内容】 中国神华(601088.SH) 公司快评:千亿规模收购助力未来发展，龙头行稳 致远 中国海油(600938.SH) 公司快评:渤海海域获得亿吨级油田发现，国内油 气持续上产 金融工程 金融工程周报:股指分红点位监控周报-股指期货主力合约贴水幅度收窄 金融工程日报:沪指震荡攀升录得六连阳，商业 ...

Market Overview - The Hong Kong stock market indices collectively rose on December 22, with the Hang Seng Tech Index increasing by 0.87%, the Hang Seng Index by 0.43%, and the China Enterprises Index also by 0.43% [1][2]. Sector Performance - Large technology stocks generally saw slight increases, with notable gains in semiconductor and optical communication sectors. Leading stock SMIC rose over 8% [2][4]. - The luxury goods sector declined, while the biopharmaceutical sector showed weakness, with several stocks experiencing significant drops [2][8]. Notable Stock Movements - The gold and precious metals sector performed well, with spot gold reaching $4,400 per ounce, marking a nearly 68% increase year-to-date, and silver hitting $69 per ounce, up approximately 139% this year [5][6]. - Semiconductor stocks also saw gains, with SMIC and Huahong Semiconductor rising over 5%. Analysts from China Galaxy Securities highlighted the AI demand driving a recovery in the storage chip market [6][7]. New Consumption Trends - New consumption concept stocks strengthened, with companies like Mixue Group rising nearly 10% and others like Lao Pu Gold and Guoquan also showing significant gains [7][8]. Biopharmaceutical Sector Insights - The biopharmaceutical sector faced challenges, with stocks like Lai Kai Pharmaceutical dropping over 8%. Analysts noted a cyclical nature in the industry, with recent supportive policies for innovative drugs potentially leading to a new development cycle [8][9]. Capital Flow and Future Outlook - Southbound funds recorded a net inflow of HKD 3.125 billion, indicating positive capital movement into the Hong Kong market [9][11]. - Analysts from Huatai Securities anticipate that the upcoming year will see significant capital flow changes due to expected RMB appreciation and improvements in market conditions, particularly benefiting dividend-paying stocks in the Hong Kong market [11].

Investment Rating - The report assigns an investment rating of "Outperform the Market" for the pharmaceutical sector, indicating a relative performance better than the benchmark index [8]. Core Insights - The pharmaceutical sector has shown resilience, with the SW Pharmaceutical Bio Index declining only 0.14% compared to the Shanghai and Shenzhen 300 Index's decline of 0.28% during the week of December 15-21 [2]. - The report highlights significant developments in AI healthcare, particularly with the launch of Ant Group's upgraded AI health app "Antifufu," which aims to enhance health management for users [2]. - Insilico Medicine's IPO is anticipated to drive innovation in drug development, with a focus on its AI-driven platform Pharma.AI and promising clinical results for its lead product Rentosertib [2]. - The approval of the Enhertu and trastuzumab combination therapy for HER2-positive breast cancer is expected to redefine first-line treatment standards in this area [2]. - The report emphasizes the potential of Chinese innovative drugs in international markets and suggests continued monitoring of key sectors such as ADCs, bispecific antibodies, and weight-loss drugs [2]. Summary by Sections Industry Performance - The pharmaceutical sector's weekly trading volume was 389.82 billion yuan, showing a slight decline compared to previous weeks, indicating a need for recovery in market sentiment [2]. AI Healthcare Developments - The "Antifufu" app connects users with 300,000 real doctors for online consultations and has over 15 million monthly active users, with 55% from lower-tier cities, showcasing the app's broad reach [2]. IPO and Drug Development - Insilico Medicine's IPO is set for December 30, with a total fundraising target of 2.277 billion HKD, primarily for clinical research of its drug pipeline [2][5]. Treatment Innovations - The Enhertu and trastuzumab combination therapy has shown a significant improvement in progression-free survival rates, marking a major advancement in treatment options for HER2-positive breast cancer [2].

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [30]. Core Insights - The MSCI China Healthcare Index has increased by 51.9% since the beginning of 2025, outperforming the MSCI China Index by 24.3%. However, there has been a recent correction of 14% in the healthcare index, which is viewed as a rebalancing of valuations and expectations, creating better investment opportunities [1][3]. - The long-term trend of Chinese innovative drugs entering international markets is expected to continue, driven by competitive advantages such as higher early-stage R&D efficiency, faster clinical recruitment, and lower clinical costs. The focus for 2026 will be on the clinical progress and data release of pipelines that have already entered international markets [3]. - The impact of the recently enacted "Biological Security Act" on Chinese CXO companies is anticipated to be limited, as it does not affect Medicaid and Medicare procurement and has clear definitions regarding related parties. The revenue from U.S. government agencies for Chinese CXO companies is relatively small [3]. Summary by Sections Industry Overview - The recent industry correction is attributed to profit-taking and the market digesting previously high valuations, particularly in the innovative drug sector. This adjustment is seen as a rebalancing of valuations and performance, leading to more attractive investment opportunities [3]. - The report emphasizes the importance of monitoring the progress of products that have already entered international markets, as their clinical trials and data releases will serve as key catalysts for stock prices in 2026 [3]. Company Ratings and Valuations - The report recommends buying the following companies: - **Sihuan Pharmaceutical (1530 HK)**: Market cap of $8,178 million, target price of $37.58, with a potential upside of 44% [2]. - **Gusongtang (2273 HK)**: Market cap of $924.7 million, target price of $44.95, with a potential upside of 52% [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,782.4 million, target price of $74.00, with a potential upside of 6% [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,842.2 million, target price of $9.40, with a potential upside of 43% [2].

Core Viewpoint - The MSCI China Healthcare Index has increased by 51.9% from the beginning of 2025 to date, outperforming the MSCI China Index which rose by 24.3% [1] Group 1: Market Performance - The recent pullback in the healthcare sector has seen the MSCI China Healthcare Index decline by 14% since October [1] - The pullback is attributed to the digestion and rebalancing of valuations and expectations, creating a favorable investment window for future opportunities [1] Group 2: Investment Recommendations - The company recommends a cautious investment approach, focusing on undervalued stocks [1] - Specific stocks recommended for purchase include: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - WuXi AppTec Co., Ltd. (02268) - China National Pharmaceutical Group (01177) - All recommended stocks have a "buy" rating [1] Group 3: Future Outlook - The trend of innovative drugs entering international markets is expected to continue into 2026, with a focus on clinical progress and data validation of pipelines that have already gone abroad [1] - The recently enacted "Biosecurity Law" is anticipated to have limited impact on the operational aspects of Chinese CXO companies [1]

Core Viewpoint - The MSCI China Healthcare Index has increased by 51.9% from the beginning of 2025 to date, outperforming the MSCI China Index which rose by 24.3% [1] Group 1: Investment Recommendations - The company recommends a cautious investment approach, focusing on undervalued stocks [1] - Specific stocks recommended for purchase include: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - WuXi AppTec Co., Ltd. (02268) - China National Pharmaceutical Group (01177) - All recommended stocks have a "Buy" rating [1] Group 2: Market Trends - The healthcare sector has recently experienced a pullback, with the MSCI China Healthcare Index declining by 14% since October [1] - The recent pullback is attributed to the digestion and rebalancing of valuations and expectations, creating a better investment window for the future [1] Group 3: Future Outlook - Looking ahead to 2026, the trend of innovative drugs entering international markets is expected to continue [1] - The focus will be on the clinical progress and data validation of pipelines that have already entered international markets [1] Group 4: Policy Impact - The recently signed and effective "Biological Safety Law" is anticipated to have limited practical impact on the operations of Chinese CXO companies [1]

12月19日，港股三大指数高开高走，截至收盘，恒生指数上涨0.75%，恒生科技指数上涨1.12%，恒生国企指数上涨0.68%。 【导读】港股三大指数集体收涨 创新药、新能源汽车等涨幅靠前 具体来看，当日权重科技股集体上涨，腾讯、快手、网易、美团、百度均涨超1%。 板块方面，当日创新药概念股涨幅靠前，其中，映恩生物涨幅达9.29%，药明生物涨幅达4.4%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 9606 | 映恩生物-B | 336.600c | 28.600 | 9.29% | | 2269 | 药明生物 | 34.160c | 1.440 | 4.40% | | 6990 | 科伦博泰生物-B | 419.200c | 14.200 | 3.51% | | 1877 | 君实生物 | 23.240c | 0.760 | 3.38% | | 2162 | 康诺亚-B | 55.500c | 1.800 | 3.35% | | 2268 | 药明合联 | 70.000c | 2.050 | 3.02% | | 1530 | ...